The trial is conducted in Europe. This clinical pharmacology trial investigates the effect of exercise on the pharmacokinetics and pharmacodynamics of inhaled insulin in subjects with type 1 diabetes.

Inclusion Criteria:

• Type 1 diabetes more than or equal to 12 months
• Baseline HbA1c less than or equal to 11%
• Body mass index (BMI) less than or equal to 29 kg/m2
• Normal lung volumes
• Treatment with intensified insulin therapy for at least 3 months

Exclusion Criteria:

• Any present or history of pulmonary disease
• Any findings from the cardiopulmonary exercise test compromising safety of moderate exercise
• Impaired hepatic or renal function
• Cardiac problems
• Uncontrolled hypertension
• Current proliferative retinopathy or maculopathy
• Treatment with drugs, which may interfere with insulin action, glucose metabolism or recovery from hypoglycaemia (judged by investigator)
• Current smoking or smoking within the last 6 months
• Blood donation (more than 500 mL) within the last nine weeks